Cargando…

SMIP-30, a potent and selective PPM1A inhibitor with potential to treat tuberculosis

Detalles Bibliográficos
Autores principales:	Xu, Shujing, Liu, Xinyong, Zhan, Peng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2022
Materias:	Highlight
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9764063/ https://www.ncbi.nlm.nih.gov/pubmed/36561990 http://dx.doi.org/10.1016/j.apsb.2022.10.001

Ejemplares similares

Targeting PELP1 oncogenic signaling in TNBC with the small molecule inhibitor SMIP34
por: Altwegg, Kristin A., et al.
Publicado: (2023)

Targeting the entry step of SARS-CoV-2: a promising therapeutic approach
por: Li, Jing, et al.
Publicado: (2020)

Potential treatment of COVID-19 by inhibitors of human dihydroorotate dehydrogenase
por: Xu, Yechun, et al.
Publicado: (2020)

‘Pyrococcus furiosus, 30 years on’
por: Kengen, Servé W. M.
Publicado: (2017)

Cadmium is a potent inhibitor of PPM phosphatases and targets the M1 binding site
por: Pan, Chang, et al.
Publicado: (2013)

CASSIS and SMIPS: promoter-based prediction of secondary metabolite gene clusters in eukaryotic genomes
por: Wolf, Thomas, et al.
Publicado: (2016)

Identification of HN252 as a potent inhibitor of protein phosphatase PPM1B
por: Lu, Zhiyuan, et al.
Publicado: (2020)

Could tivozanib be a new potent pan-VEGF inhibitor in RCC therapy?
por: Mihály, Zsuzsanna, et al.
Publicado: (2012)

Compartmentalized multicellular crosstalk in lymph nodes coordinates the generation of potent cellular and humoral immune responses
por: Poirot, Justine, et al.
Publicado: (2021)

COVID-19 and Tuberculosis
por: Yang, Heng, et al.
Publicado: (2020)

Loss of chromatin modulator Dpy30 compromises proliferation and differentiation of postnatal neural stem cells
por: Zhao, Ting, et al.
Publicado: (2019)

Immunological consequences of strain variation within the Mycobacterium tuberculosis complex
por: Tientcheu, Leopold D., et al.
Publicado: (2017)

Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children
por: Jefferson, Tom, et al.
Publicado: (2014)

Dental pulp stem cells for treating neurodegenerative diseases
por: Shamir, Christopher, et al.
Publicado: (2015)

Diabetes Treatment: Selective Synthetic Receptor for Glucose
por: Shirinfar, Bahareh, et al.
Publicado: (2019)

A Radical Twist to the Versatile Behavior of Iron in Selective Methane Activation**
por: Ruitenbeek, Matthijs, et al.
Publicado: (2014)

A gating mechanism of K2P channels by their selectivity filter
por: Yang, Fan
Publicado: (2022)

From aspiration to implementation of the 30% solution
por: Pimm, Stuart L
Publicado: (2023)

Bibliometric analysis and visualization of research trends on HIV-1 capsid inhibitors (2000–2022)
por: Sun, Lin, et al.
Publicado: (2023)

MXene-Graphene Composites: A Perspective on Biomedical Potentials
por: Mostafavi, Ebrahim, et al.
Publicado: (2022)

The neuroprotective effects of human growth hormone as a potential treatment for amyotrophic lateral sclerosis
por: Chung, Jin-Young, et al.
Publicado: (2015)

Spinal cord concussion: studying the potential risks of repetitive injury
por: Fischer, Itzhak, et al.
Publicado: (2016)

Sequence capture by hybridization reveals elusive hydrocarbon degradation potential
por: von Netzer, Frederick
Publicado: (2017)

Make immunological peace not war: Potential applications of tolerogenic dendritic cells
por: Walton, Emma Louise
Publicado: (2017)

Regenerative potential of targeting glycogen synthase kinase-3 signaling in neural tissues
por: Jung, Eui-Man, et al.
Publicado: (2015)

Targeting α7 nicotinic acetylcholine receptors: a future potential for neuroprotection from traumatic brain injury
por: Shin, Samuel S., et al.
Publicado: (2015)

The determinants associated with zoonotic potential of influenza A viruses: BTN3A3 evasion mediated by residue mutation in the nucleoprotein
por: Tian, Lili, et al.
Publicado: (2023)

Targeting folliculin to selectively inhibit mTORC1: a promising strategy for treating nonalcoholic fatty liver disease
por: Ling, Yan, et al.
Publicado: (2022)

Phase 1 study of TRU-015, a CD20-directed small modular immunopharmaceutical (SMIP™) protein therapeutic, in subjects with rheumatoid arthritis
por: Burge, DJ, et al.
Publicado: (2007)

Potential mechanisms by which impaired ketogenesis links metabolism to T‐cell dysfunction in patients with severe COVID‐19
por: Wang, Bin, et al.
Publicado: (2022)

Plasma pTau181 as a biomarker for Alzheimer's disease
por: Meng, Jie, et al.
Publicado: (2020)

ELANE: an emerging lane to selective anticancer therapy
por: Peng, Boqiang, et al.
Publicado: (2021)

Therapeutic utility of immunosuppressive TREM2+ macrophages: an important step forward in potentiating the immune checkpoint inhibitors
por: Alkan, Fulya Koksalar, et al.
Publicado: (2020)

Newly synthesized M(pro) inhibitors as potential oral anti-SARS-CoV-2 agents
por: Li, Lin, et al.
Publicado: (2021)

Workshop on PPM
Publicado: (1978)

PPM LPI
por: Frammery, B
Publicado: (1987)

PPM LPI
Publicado: (1987)

TRU-015, a small modular immunopharmaceutical (SMIP™) drug candidate directed against CD20, demonstrates clinical improvement in subjects with rheumatoid arthritis
por: Burge, DJ, et al.
Publicado: (2007)

Circular RNA vaccine, a novel mRNA vaccine design strategy for SARS‐CoV‐2 and variants
por: Su, Peng, et al.
Publicado: (2022)

Immune receptor mimicking hormone receptors: a new guarding strategy
por: Liu, Xueru, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_kueo6tcrbln575v31va68e485r